Mode
Text Size
Log in / Sign up
Phase 3 Completed N=528 Randomized Quadruple-blind Treatment

Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression

Source: ClinicalTrials.gov NCT02600507 ↗
Enrolled (actual)
528
Serious AEs
0.2%
Results posted
May 2023
Primary outcomePrimary: Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -16.2; -16.9; -14.5 score on a scale — p=0.021
◆ Published Evidence
Established
27citations · ~9 / year
Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial.
Bipolar disorders · 2023 · Open access · Likely link

Summary

The study will evaluate the efficacy and safety of ITI-007 adjunctive to lithium or valproate in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major depressive episode.

Linked Publications

  • Adjunctive lumateperone (ITI-007) in the treatment of bipolar depression: Results from a randomized placebo-controlled clinical trial.
    Bipolar disorders · 2023 · 27 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score
-16.2; -16.9; -14.5 0.021 sig
SECONDARY
Change From Baseline in Clinical Global Impression Scale-Bipolar Version-Severity (CGI-BP-S) Depression Score
-1.7; -1.8; -1.5 0.008 sig

Eligibility Criteria

Inclusion Criteria

  • male or female subjects of any race, ages 18-75 inclusive, with a clinical diagnosis of Bipolar I or Bipolar II disorder
  • experiencing a current major depressive episode
  • treatment with either lithium or valproate and inadequate therapeutic response of depressive symptoms

Exclusion Criteria

  • any subject unable to provide informed consent
  • any female subject who is pregnant or breastfeeding
  • any subject judged to be medically inappropriate for study participation
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02600507) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search